Publications by authors named "Usha D Appadu"

Background: Grade I meningiomas are generally benign and non-invasive whereas Grade II (atypical) and Grade III (malignant) meningiomas tend to be invasive with a high risk of recurrence. SPARC, secreted protein, acidic and rich in cysteine, is a multifunctional glycoprotein which has been proposed to be a potential diagnostic marker of invasive meningiomas. There has been increased reporting of atypical meningiomas since the current World Health Organization (WHO) included brain invasion as a grading criterion for classification of these particular meningiomas.

View Article and Find Full Text PDF

MMPs (matrix metalloproteinases), ADAMs (a disintegrin and metalloproteinase) and TIMPs (tissue inhibitors of metalloproteinases) are implicated in invasion and angiogenesis: both are tissue remodeling processes involving regulated proteolysis of the extracellular matrix, growth factors and their receptors. The expression of these three groups and their correlations with clinical behaviour has been reported in gliomas but a similar comprehensive study in meningiomas is lacking. In this study, we aimed to evaluate the patterns of expression of 23 MMPs, 4 TIMPs, 8 ADAMs, selective growth factors and their receptors in 17 benign meningiomas using a quantitative real-time polymerase chain reaction (qPCR).

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Usha D Appadu"

  • - Usha D Appadu's research primarily focuses on the molecular and cellular aspects of meningiomas, specifically examining the gene expression profiles related to tumor invasion and angiogenesis.
  • - In her 2020 study, Appadu explored the relationship (or lack thereof) between the expression of SPARC and the invasiveness of different grades of meningiomas, providing insights into the diagnostic implications of this glycoprotein.
  • - In a prior 2016 study, she conducted a comprehensive analysis of the expression of various matrix metalloproteinases (MMPs), a disintegrin and metalloproteinase (ADAMs), and tissue inhibitors (TIMPs) in benign meningiomas, highlighting their potential roles in tumor behavior and extracellular matrix remodeling.